This week, the World Health Organization (WHO) will meet with the Russian Direct Investment Foundation (RDI), which will discuss the schedule of the following steps to evaluate the Russian Vaccine against Coronavirus Satellite V “in the framework of the inclusion procedure on the list of preparations recommended for Emergency use (Emergency Use Listing, Eul). This TASS reported in WHO headquarters in Geneva.
In the organization recalled that in October the RDPI “signed all the necessary legal agreements necessary for evaluation within the EUL”. This step is a “prerequisite for all applicants.” In addition, on the path of recognition of the drug, the Russian side should provide updated information about “corrective and preventive measures (CAPAS)” concerning inspections in enterprises. As soon as the application and all materials are obtained and reviewed, “the applicant will decide on the need for a verified inspection on the spot,” added to WHO.
On Friday, November 12, Assistant Director General of WHO Marianget Simao reported that this week the organization intends to meet the “satellite V”. She noted that WHO “Have questions about Inspection in the National Research Center of Epidemiology and Microbiology named after N. F. Gamalei, on production inspection.”
Earlier at the UK embassy in Moscow, it was stated that the approval of the “satellite V” would be a positive step by WHO, as it could contribute to the adoption of the drug around the world. In particular, the diplomance commented on the possible inclusion of vaccine in the registry of funds for use in emergency situations.